The crystal structure of bisphenol A (BPA) bound to the human estrogen-related receptor γ (ERRγ, NR3B3) explained, at the atomic level, how this high-volume industrial chemical binds an orphan nuclear receptor with an apparent KDK_D of roughly 5.5 nM while preserving the receptor's constitutive transcriptional activity. What the 2007 structure paper explicitly left open — and what remains open after nineteen years of follow-up work — is the physiological and toxicological meaning of that interaction: whether BPA occupancy of ERRγ actually causes any of the reported low-dose endocrine-disrupting effects in vivo, which endogenous genes ERRγ regulates in its target tissues and whether environmental BPA exposure alters them, and whether ERRγ functions ligand-independently in vivo or has a naturally occurring endogenous ligand. Zebrafish data establish ERRγ as an in vivo BPA receptor but only at micromolar doses; the first candidate endogenous ligands (the gut-microbiota metabolites indole and skatole) were proposed only in 2025 and remain unvalidated physiologically. A mammalian in vivo, receptor-loss-of-function test at environmentally relevant exposure has never been reported.

Background

Bisphenol A (BPA) is an industrial chemical used chiefly in polycarbonate plastics and epoxy resins, and human exposure through food contact materials is ubiquitous. It is the most-studied endocrine-disrupting chemical (EDC) — an exogenous compound that interferes with hormone action — with a large literature reporting effects on reproduction, brain development, and metabolism at doses far below those causing classical toxicity (the 'low-dose' hypothesis), although the receptors responsible and the shape of the dose–response remain contested.

Nuclear receptors are ligand-regulated transcription factors; ERRγ (estrogen-related receptor γ, NR3B3) is one of the 48 human nuclear receptors and, despite sharing homology with the estrogen receptors, does not bind estrogens. It is an orphan receptor — no endogenous ligand is firmly established — and is constitutively active: even with an empty ligand-binding pocket, its C-terminal 'activation helix' (helix 12, the molecular switch that in classical nuclear receptors moves only upon ligand binding) already sits in the active conformation, and its activity is controlled mainly by the abundance of coactivators such as PGC-1α (peroxisome proliferator-activated receptor γ coactivator-1α), a master regulator of energy-metabolism genes. ERRγ is strongly expressed in placenta, fetal brain, heart, liver, pancreas, and kidney.

In 2006–2007 the Kyushu group showed by radioligand binding that BPA binds ERRγ with an apparent dissociation constant KD≈5.5K_D \approx 5.5 nM — far tighter than BPA binds the classical estrogen receptors — and solved the crystal structure of the ERRγ ligand-binding domain (LBD) in complex with BPA. The structure showed BPA anchored in the pocket by hydrogen bonds from its two phenolic hydroxyls to Glu275/Arg316 and Asn346, surrounded by hydrophobic contacts (notably Tyr326), with essentially no change to the apo receptor: BPA simply preserves the active conformation, explaining why it behaves as a weak 'preserving' agonist and blocks the deactivation of ERRγ by 4-hydroxytamoxifen (4-OHT), an estrogen-receptor drug that also binds ERRγ as an inverse agonist. This was the first nuclear-receptor structure with an endocrine disruptor, and it made ERRγ a candidate receptor for BPA's unexplained low-dose effects.

The mechanistic picture has since been consolidated and refined: later crystal, biophysical, and molecular-dynamics work on dozens of bisphenols, alkylphenols, and related EDCs showed that ERRγ ligands act by rigidifying parts of an already-active receptor rather than by the classical induced-fit repositioning of helix 12; isothermal-titration-calorimetry affinities for the most potent environmental ERRγ ligands fell in the 50–500 nM range, in agreement with cellular activation potencies but in unresolved tension with the 5.5 nM radioligand figure. Two gaps identified in the 2007 paper have persisted. First, a pharmacokinetic gap: BPA is rapidly conjugated and cleared, and free (unconjugated) BPA concentrations in human blood and target tissues are debated, so whether receptor occupancy ever occurs at environmental exposure is itself disputed (measured baseline BPA in human placental tissue, one of the highest-ERRγ tissues, is 0.04–5.1 nM — near the nominal KDK_D). Second, a physiological gap: the endogenous ERRγ gene programs in its target tissues and their sensitivity to BPA in vivo have never been systematically mapped, and the identity of any endogenous ERRγ ligand remains unknown, with the gut-microbiota metabolites indole and skatole reported only in 2025 as first, still-unvalidated candidates binding in the low-micromolar range.

Problem Statement

Determine the physiological and toxicological significance of the bisphenol A–ERRγ interaction identified structurally in 2007, as one connected objective with three jointly supporting questions: (1) Causality — does BPA binding to ERRγ cause, at environmentally relevant exposure concentrations and doses, specific endocrine-disrupting effects in vivo, in any tissue (including fetal brain and placenta) and at any developmental stage? Causal in vivo evidence at environmentally relevant exposure settles this question in either direction — establishing ERRγ mediation, or rigorously excluding it; the experimental route is not constrained, and attributing effects to ERRγ rather than to competing BPA targets (ERα, ERβ, GPER, androgen receptor) and justifying exposure relevance remain scientific requirements of the evidence offered, not a mandated design. A rigorous negative result — demonstration that ERRγ does not mediate BPA's previously reported low-dose endocrine-disrupting effects (the endpoint classes reported in the literature and listed in the Background, e.g., reproduction, brain development, and metabolism) — resolves the causality question just as a positive result does, provided the effects examined cover the relevant classes of previously reported low-dose effects rather than only the endpoints actually measured. (2) Target-gene program — identify which endogenous genes ERRγ regulates in its principal expression tissues (e.g., placenta and fetal brain) and determine whether BPA exposure at environmental concentrations alters that program in vivo in a physiologically significant way, including the direction, extent, and developmental timing of any alteration. (3) Endogenous ligand status — establish whether ERRγ functions ligand-independently in vivo (which requires evidence that no endogenous ligand is present at active concentrations in ERRγ-expressing tissues and that the receptor's in vivo activity does not require one), or identify its physiological endogenous ligand(s) with supporting evidence; relevant evidence types include direct binding affinity, structural characterization of the complex, modulation of receptor activity and coactivator recruitment, presence at active concentrations in ERRγ-expressing tissues, and in vivo functional validation of the ligand's gene-regulatory activity — not a fixed conjunction that must be satisfied item by item, but evidence whose total weight bears on the claim. The three parts jointly establish one scientific objective: whether the high-affinity BPA–ERRγ interaction is an accident of receptor chemistry or a functioning toxicological and physiological pathway.

References

  1. Matsushima A, Kakuta Y, Teramoto T, Koshiba T, Liu X, Okada H, Tokunaga T, Kawabata S, Kimura M, Shimohigashi Y. 'Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma.' Journal of Biochemistry 142(4):517-524 (2007). DOI 10.1093/jb/mvm158, https://doi.org/10.1093/jb/mvm158
  2. Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, Shimohigashi Y. 'Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity.' Toxicology Letters 167:95-105 (2006). DOI 10.1016/j.toxlet.2006.08.012, https://doi.org/10.1016/j.toxlet.2006.08.012
  3. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y. 'Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma.' Environmental Health Perspectives 116(1):32-38 (2008). DOI 10.1289/ehp.10587, https://doi.org/10.1289/ehp.10587
  4. Takeda Y, Liu X, Sumiyoshi M, Matsushima A, Shimohigashi M, Shimohigashi Y. 'Placenta expressing the greatest quantity of bisphenol A receptor ERRgamma among the human reproductive tissues: predominant expression of type-1 ERRgamma isoform.' Journal of Biochemistry 146(1):113-122 (2009). DOI 10.1093/jb/mvp049, https://doi.org/10.1093/jb/mvp049
  5. Liu X, Matsushima A, Okada H, Shimohigashi Y. 'Distinction of the binding modes for human nuclear receptor ERRγ between bisphenol A and 4-hydroxytamoxifen.' Journal of Biochemistry 148(2):247-254 (2010). DOI 10.1093/jb/mvq056, https://doi.org/10.1093/jb/mvq056
  6. Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, Labesse G, Bourguet W, Balaguer P. 'Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes.' Proceedings of the National Academy of Sciences USA 109(37):14930-14935 (2012). DOI 10.1073/pnas.1203574109, https://doi.org/10.1073/pnas.1203574109
  7. Tohmé M, Prud'homme SM, Boulahtouf A, Samarut E, Brunet F, Bernard L, Bourguet W, Gibert Y, Balaguer P, Laudet V. 'Estrogen-related receptor γ is an in vivo receptor of bisphenol A.' FASEB Journal 28(7):3124-3133 (2014). DOI 10.1096/fj.13-240465, https://doi.org/10.1096/fj.13-240465
  8. Song H, Zhang T, Yang P, Li M, Yang Y, Wang Y, Du J, Pan K, Zhang K. 'Low doses of bisphenol A stimulate the proliferation of breast cancer cells via ERK1/2/ERRγ signals.' Toxicology in Vitro 30(1 Pt B):521-528 (2015). DOI 10.1016/j.tiv.2015.09.009, https://doi.org/10.1016/j.tiv.2015.09.009
  9. Pouzaud F, Thierry-Mieg M, Burga K, Vérines-Jouin L, Fiore K, Beausoleil C, Michel C, Rousselle C, Pasquier E (ANSES Working Group on Endocrine Disruptors). 'Concerns related to ED-mediated effects of Bisphenol A and their regulatory consideration.' Molecular and Cellular Endocrinology 475:92-106 (2018). DOI 10.1016/j.mce.2018.02.002, https://doi.org/10.1016/j.mce.2018.02.002
  10. Thouennon E, Delfosse V, Bailly R, Blanc P, Boulahtouf A, Grimaldi M, Barducci A, Bourguet W, Balaguer P. 'Insights into the activation mechanism of human estrogen-related receptor γ by environmental endocrine disruptors.' Cellular and Molecular Life Sciences 76(23):4769-4781 (2019). DOI 10.1007/s00018-019-03129-x, https://doi.org/10.1007/s00018-019-03129-x
  11. Zou Z, Harris LK, Forbes K, Heazell AEP. 'Sex-specific effects of bisphenol A on the signaling pathway of ESRRG in the human placenta.' Biology of Reproduction 106(6):1278-1291 (2022). DOI 10.1093/biolre/ioac044, https://doi.org/10.1093/biolre/ioac044
  12. Matsushima A, Teramoto T, Kakuta Y. 'Crystal structure of endocrine-disrupting chemical bisphenol A and estrogen-related receptor γ.' Journal of Biochemistry 171(1):23-25 (2022). DOI 10.1093/jb/mvab145, https://doi.org/10.1093/jb/mvab145
  13. Yuan M, Zeng C, Lu H, Yue Y, Sun T, Zhou X, Li G, Ai N, Ge W. 'Genetic and Epigenetic Evidence for Nonestrogenic Disruption of Otolith Development by Bisphenol A in Zebrafish.' Environmental Science & Technology 57(43):16190-16205 (2023). DOI 10.1021/acs.est.3c04336, https://doi.org/10.1021/acs.est.3c04336
  14. Zheng Y, Du Y, Zhang H, Lv H, Yan Z, Dong N, Li Q, Wang T. 'Research Progress in Estrogen-related Receptor Gamma (ERRγ) Agonists and Inverse Agonists.' Current Medicinal Chemistry 31(24):3653-3667 (2024). DOI 10.2174/0929867330666230518140631, https://doi.org/10.2174/0929867330666230518140631
  15. Sadasivam N, Park WR, Choi B, Jung YS, Choi HS, Kim DK. 'Exploring the impact of estrogen-related receptor gamma on metabolism and disease.' Steroids 211:109500 (2024). DOI 10.1016/j.steroids.2024.109500, https://doi.org/10.1016/j.steroids.2024.109500
  16. Wang Q, Huang N, Psaltis JB, Gahtani RM, Yan G, Lu D, Cahalan SR, Shi X, Copeland RL, Haddad BR, Martin MB. 'Activation of estrogen-related receptor γ by calcium and cadmium.' Frontiers in Endocrinology 15:1400022 (2024). DOI 10.3389/fendo.2024.1400022, https://doi.org/10.3389/fendo.2024.1400022
  17. Shuai YY, Zhang HY, Chen R, Wang BL, Ding P, Dong Y, Sun MZ, Wu XS, Xu Y, Zhang Y, Liu JS, Wang N, Xu TT. 'Identification of indoles as potential endogenous ligands of ERRγ and their modulation on drug binding.' Acta Pharmacologica Sinica 46(9):2574-2582 (2025). DOI 10.1038/s41401-025-01550-6, https://doi.org/10.1038/s41401-025-01550-6
  18. Lauby SC, Wylie DC, Lapp HE, Salazar M, Margolis AE, Champagne FA. 'Postnatal maternal care normalizes the medial preoptic area DNA methylome following prenatal bisphenol exposure.' BMC Genomics (2026). DOI 10.1186/s12864-026-13265-x, https://doi.org/10.1186/s12864-026-13265-x (peer-reviewed version; first posted as bioRxiv preprint 10.1101/2025.10.03.680379)
  19. Radwan MO, Guin S, Burris TP. 'Pharmacology of estrogen-related receptors (ERRs) agonists.' RSC Chemical Biology 7(7):1265-1277 (2026). DOI 10.1039/d6cb00077k, https://doi.org/10.1039/d6cb00077k